LONDON (Alliance News) - Data science company IXICO PLC said Thursday it has extended its contract with an undisclosed biopharmaceutical company, raising its total value to EUR1.3 million.
The deal between IXICO and the unnamed company has an Alzeheimer's disease focus. Its extension from September 2020 to May 2021, as well as the addition of new clinical sites, has improved the contract's value by 63% from the EUR800,000 announced in July last year.
"This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes," said IXICO Chief Executive Giulio Cerroni.
Shares in IXICO were down 2.0% at 29.90 pence on Thursday.
Ixico (IXI)